Clinical courses of patients 1 and 2. (A) Clinical course of patient 1 with X-severe combined immunodeficiency who received donor-derived Adv-specific VSTs after their second HCT with resolution of Adv. (B) Clinical course of patient 2 with combined immunodeficiency who received third-party–derived trivalent VSTs specific for EBV, CMV, and Adv for the treatment of Adv. BMT, bone marrow transplant; PBSC, peripheral blood stem cell; PTCy, posttransplant cyclophosphamide; VL, viral load.